Author: admin

New guide educational Audiovisual directed to patients with COPD and their families.

New guide educational Audiovisual directed to patients with COPD and their family members.

presentation at the 44th National Congress SEPAR.

-the aim of the guide is promoting the well-being of patients with COPD and their families and carers, as well as raise awareness among patients of how risk factors affect its prognosis and evolution

-The guide consists of five chapters in audio-visual support and additional material which addresses all aspects about COPD

Spain, 2011-July the guide educational Audiovisual for patients with COPD and their families, by SEPAR and sponsored by Nycomed and MSD respiratory, is an educational guide on DVD that teaches a series of concepts and skills, with the aim of getting patients to cooperate in their treatment and rehabilitation and reduce your anxiety to the disease.

This guide, presented in the framework of the forty-fourth Congress of SEPAR recently held in Oviedo, aims to promote the well-being of patients with COPD and their family members/caregivers in response to the needs of knowledge and just-in-time training. In addition, provides information about the physical process and factors of stress for the patient and the caregiver, and is provided to the patient’s techniques and skills to facilitate the incorporation of healthy lifestyle habits that have proven to reduce exacerbations and slow down the progression of the disease. Another objective is to educate the patients how they affect risk factors their prognosis and evolution, get patients to cooperate in their treatment and rehabilitation (model empowerment) and reduce their anxiety to the disease.

Guide has a duration of 50 minutes and consists of forty minutes of literary history and ten minutes for annexes. The contents of the Guide are structured into chapters and it is possible to navigate between them, so that they can select the chapters of the guide that most interest you in every moment and review them as many times needed.

Consists of five chapters: information about COPD diagnosis, how to live with the disease, aggravation, and when the disease progresses; also has additional content explaining in what consists the inhalation technique, breathing physiotherapy and indications to quit smoking.

The COPD, a highly disabling disease

The chronic nature of the disease and disabling symptoms that produces many times people care to a relative or a friend are forced to accept large physical, emotional, and social responsibilities that often cause situations that overflow their capacity of attention and care to not understand or know handle the after-effects of the disease.

Chronic obstructive pulmonary disease (COPD) is a disease primarily associated with tobacco that is characterized by the difficulty of the passage of air by the bronchi. This term describes two related lung diseases: chronic bronchitis and pulmonary emphysema. In addition to affecting the lungs, COPD also can cause other health problems, being the most frequent high blood pressure, ischemic heart disease, heart failure, diabetes, osteoporosis and ansiedad-depresión.

COPD is a serious problem of public health is not something novel. Spain, Studio IBERPOC is the prevalence of this disease by 9.1% in persons aged 40-69 and EPI-SCAN makes 10.2 per cent for a population of 40 to 80 years of age. What is surprising, according to this study, the high degree of under-diagnosis (73%) and below treatment (54%) of the disease in Spain, as well as the fact that the patients who were diagnosed had a more severe illness, increased consumption accumulated of snuff and worse quality of life related to the health.

Read More

Brachytherapy improves the efficiency of the treatment of cancer and prevents side effects according to Nucletron.

brachytherapy improves efficiency in thecancer treatment and avoid side effects according to Nucletron.

Sevilla hosts the 2nd Congress of societiesMedical physics and protection radiation.


– thebrachytherapy has fewer side effects than external radiation andIt decreases the risk of later incontinence or dysfunctionErectile.

– inour country, prostate cancer is the second most common tumor between themen after cancer of lung

-NucletronIt shows their latest equipment for exact knowledge of the location,dimension and variations of the tumor during the whole treatment.

Seville, may 2011. – brachytherapyin the treatment of prostate cancer reduces the processing time andIt favours the speedy recovery of the patient. Nucletron, companydevelops innovative Oncology solutions focused to theimprovement of the quality of life of the patient, has been known in Sevilla itsrecent advances in brachytherapy for the treatment of prostate canceron the occasion of the second Congress of the Spanish companies ofMedical physics and radiological protection, from 10 to 13 May.

prostate cancer is cancer morecommon among the European men, while their mortality declines each yearas a result of early diagnosis and therapeutic innovations.

according to the data submitted by Nucletron, thebrachytherapy has the advantage of having fewer side effects than theexternal radiation (EBT). In other words, the risk of laterincontinence and erectile dysfunction is low when this has been usedtechnique. These factors minimize the impact on the quality of life of thepatient, since a shorter treatment received and recovers soon,can continue with its daily activity in a way almost immediately.


the prostate cancer in Spain.

in our country, prostate cancer is thesecond most common tumor among males after lung cancer . according to data from global incidence of cancer in Spain, it is estimated thatby 2015 the incidence of prostate cancer will be approximately 16,000cases.

Furthermore, it is observed that increasingly affects toyounger men, in particular, about 50 years. According to thespecialists, this is probably due to the influence of factorsenvironmental and styles of life, as well as the development of programmes ofscreening in primary care and specialty centers and increasedsocial awareness.


about brachytherapy.

brachytherapy involves the inclusion ofradioactive sources in the patient, is a minimally invasive butthat it offers very good results to radiate the tumor from within. Thebrachytherapy helps health professionals reach a very highprecision when it comes to delivering the doses of radiation, which allows to reducethe risk of tissue and healthy organs surrounding the tumor will bedamaged.

against other types of radiation therapy as theexternal radiation (EBT), brachytherapy releases the necessary dose ofradiation in a smaller time period, the treatment lasts from one to twodays from the seven weeks that can prolong the EBT and accuracy toget brachytherapy reduces the risk of tissue and healthy organssurrounding the tumor will be damaged, at the time that minimize the effectsside and significantly reduce the time of recovery of the patient

the II Congress set of societiesSpanish for medical physics and radiological protection will be held from 10 to 13May 2011 in Seville, with the motto “quality and safety in the use of””radiation”.

according to Eduardo Rodriguez, CEO of Nucletron forthe South of Europe, “ En Nucletron continueprogress in the research, development and dissemination of brachytherapy,driven by good performance in both directions, both in the improvement ofthe quality of life and patient recovery, as benefits arising interms of cost savings and optimization of resources is this technologyfor hospitals, to reduce the time of application and theaccuracy of the treatment ”.

the new planning system forRadiotherapy, Oncentra ® and some of its applications for the treatment of theprostate cancer and AccuBoost, first technology used treatmentof brachytherapy in way non-invasive for the treatment of breast cancer,These are some of the equipment provided by Nucletron in 2nd CongressSet of Spanish societies of Fïsica medical and protection radiation.


about Nucletron.

Nucletron develops innovative solutions forRadiology Oncology, to improve the effectiveness of treatments and careto the patient. Nucletron is a world leader in brachytherapy. Since its inception, in1975, bet for innovation and the close collaboration with clinical teamsindividual to offer more advanced forms of radiation andefficient, integrated products, software and services.

with headquarters in the Netherlands and offices in 16countries, provides equipment and services to more than 3,000 institutions in 120countries. In Spain, with presence and activity since 1975, brings his equipment to more than 230 centersoncologic.

Nucletron, with 500 employees inin 2010 all over the world, reached a turnover of 130 million Euros.


Read More

The Russian Federation sent the first Nordion medical isotope sample.

Russian Federation sends the first sample of isotope medical Nordion.

-Nordion begins the process of evaluation for molybdenum-99 provided by Russia

Ottawa, December of 2010. “Nordion Inc., a leading provider of products and services for the global market of the health sciences, announced last Thursday that it has sent its first sample of molybdenum-99 (Mo-99) from its partner of the Russian Federation, the company open joint Isotope values” (Isotope).

In September 2010 Nordion reached an Isotope supply agreement for carrying out residual Mo-99 supply until the year 2020. This recent sample of Mo-99 will be evaluated in Ottawa, Canada processing facilities. It is necessary to get the part of qualification for the registration of the product and regulatory approvals process before that company begins to receive the supply of the distribution of license.

“The sending of this first exhibition of Mo-99 is a key achievement in our Isotope supply agreement.” “In collaboration with Isotope, we hope complete the evaluation and advance supply customers with greater stability in its chain of supplies,” said Jill Chitra, senior Vice President of quality and regulatory affairs of Nordion. “We are planning to receive supplies for shipment in the first half of fiscal 2011 year, still scheduled arrival time to help mitigate the impact of the stop of reactor National Research Universal (NRU), expected by the middle of the month of May 2011.”

The Mo-99 Nordion with Isotope supply agreement provides a supply of support for customers of the company, and is expected to improve the reliability of the company’s supply chain

Preparation for shipment of the first samples, the Government of the Russian Federation and Rosatom State Corporation have invested in new and existing infrastructure. December 18, 2010, began the first production line for Mo-99 at Atomic assessment Research Institute of Dimitrovgrad, Russia.

“The release of this production complex is an outstanding event.” “The combination of a production modern radiochemical with several reactors in a unique facility provides an uninterrupted supply of isotopes for the future,” commented Andrey Silkin, CEO of Isotope. “With one growing population and a growing demand for diagnosis, the moment of appearance of our supply in the market fits perfectly with the world needs”.

Doctors use medical isotopes to achieve a better diagnosis and treatment of several diseases, including heart and neurological diseases, and various types of cancer. According to the World Nuclear Association, over 10,000 hospitals worldwide use radioisotopes in medicine, and about 90% of procedures are for diagnosis. MO – 99, and more specifically the isotope medical derived technetium – 99 m is used in approximately 80% of nuclear medical procedures around the world, up to 70,000 every day.

About Nordion

Nordion Inc. (TSX: NDN;) NYSE: NDZ) is a company of the health sciences global products and leading services in the market for the prevention, diagnosis and treatment of disease. We are a leading supplier of innovative technologies for use in medical imaging and radiation therapy, and sterilization technologies that benefit the lives of millions of people in more than 60 countries around the world. Our products and services are used daily by the biotechnology and pharmaceutical companies, manufacturers of medical devices, hospitals, clinics and laboratories of research Nordion has more than 600 staff highly qualified in four locations.

About Rosatom

Rosatom, the State Atomic Energy Corporation, is the main utility of Russia company, and produces more than 40% of the electricity in Western Russia. Rosatom is in first place in the construction of nuclear reactors worldwide, in second place in reserves of uranium and fourth position in nuclear energy generation, which provides 40% of global uranium enrichment services and 17 per cent of the global nuclear fuel fabrication. Rosatom became a State company in the year 2007, and currently consists of more than 250 companies and scientific institutions in Russia, including civilian nuclear companies, research organizations, and the only nuclear naval fleet in the world.

about the open company of joint values “Isotope” (Isotope or JSC Isotope)

service provides Isotope as a link between the isotopes of Rosatom and end-users in the markets of Russia producer and international. The main areas of activity of Isotope include: supply of isotopes for domestic and international markets; sales and marketing of products, instruments and devices for medical and commercial use; issues related to the safety of radiation and isotope technology development.

Read More

The University Hospital of Getafe form X ray technicians.

Form the University Hospital of Getafe Radiology technicians

image for diagnosis between cycles more defendants.

Spain, 2010-December The University Hospital of Getafe and the center of studies professionals Saint Gemma Galgani, signed a collaboration agreement for the delivery of the formative cycle of higher level (CFGS) called “Image for the diagnosis”, in the premises of the health centre. It is one of the most demanded cycles between students from Madrid.

This training cycle is intended to train future technicians Radiology whose powers include the get graphic records through testing equipment x-ray, MRI, Computerizada Axial Tomography (CT) and Nuclear Medicine equipment, which are then analyzed by specialist to obtain a clinical diagnosis.

“Image for diagnosis” is one of the formative cycles of degree higher demand among students from Madrid and the University Hospital of Getafe currently available equipment for the completely renovated and modern radiology in which students will learn the latest developments in the field of image radiological.

Among his most innovative teams include two resonances of autocampo and two scanners multicorte, as well as PET-CT in Nuclear Medicine Service. All teams this digitized by the PACS System and reports are made via voice recognition techniques.

The radiology service of the University Hospital of Getafe has a wide portfolio of services which include advanced techniques such as cardiac magnetic resonance imaging, interventional vascular radiology, or the vertebroplastia. During the past year was tested more than 155,000 conventional radiology, 10.737 resonances, more than 4,000 mammograms and nearly 15,000 TC.With the signing of this Convention, the University Hospital of Getafe confirms your bet by the teaching at all levels hospital.

Read More

Chondroitin sulfate shows its effectiveness condroprotectora with a new method of measurement: nuclear magnetic resonance (NMR).

chondroitin sulfate shows its effectiveness condroprotectora with a new method of measurement: nuclear magnetic resonance (NMR).

in the Congress annual Society International’s research in osteoarthritis (OARSI), held in Brussels.

-A multicenter clinical trial, randomized, double-blind, placebo-controlled, carried out by the Group of Prof. Jean-Pierre Pelletier reveals new clinical evidence: patients treated with chondroitin sulfate have experienced a reduction in the loss of the volume of the cartilage in the lateral compartment of the knee against placebo

Barcelona, October 2010.- during the celebration of the annual Congress of the international society of research in osteoarthritis (OARSI) that has taken place in Brussels, the renowned Canadian rheumatologist Prof. Pelletier has presented a clinical trial carried out in five prestigious Canadian hospitals. The data show new evidence on chondroitin sulfate to measure its modifier effect on the structure of the joint artrósica through an objective technique such as Nuclear magnetic resonance (NMR).

The MRI allows to measure the effect of the condroprotectores in 6 months, 1 year and 2 years. With this study, Prof. Pelletier demonstrated that patients treated with chondroitin sulfate have experienced a reduction in the loss of volume of cartilage in the lateral compartment of the knee with placebo. Chondroitin sulfate was also able to reduce the size of the lesions of bone subcondral.

These results corroborate data published recently in the literature in other clinical trials conducted with chondroitin sulfate, such as the STOPP study [1], the clinical trial conducted by Michel and cols [2], and the meta-analysis published by Prof. Hochberg [3].

This new technique of measuring leads to existing ones, the x-rays and arthroscopy, because it is much more reliable and less harmful for the patient, as well as presenting a greater sensitivity to x-rays, given that the effect of chondroitin sulfate is seen already after the first 6 months of treatment.

The NMR confirms once again the positive effects of chondroitin sulfate in the treatment of osteoarthritis. Chondroitin sulphate acts 3 structures concerned in the process artrósico: reduces the deterioration of the cartilage, reduces the inflammation of the synovial membrane and re-equilibra metabolism of bone subcondral.

OARSI

OARSI is the first international organization of scientists and health professionals who work for the prevention and treatment of osteoarthritis through the promotion and presentation of studies, training and dissemination of new knowledge at the global level.

References

[1] Kahan to et to the. Long-Term Effects of Chondroitins 4 and 6 Sulfate on Knee Osteoarthritis. Arthritis Rheum. 2009 Feb; 58 (11): 524-533

[2] Michel B, et to the. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee. A randomized, controlled trial. Arthritis Rheum 2005, 52 (3): 779-786

[3] Hochberg MC. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage. 2010 Jun; 18 Suppl. 1:S28 – 31.

Read More

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips